At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 31 enrolled
Drug / intervention
Pegylated Interferon (PEG-IFN) alfa-2adrug
Likely dose
Pegylated Interferon (PEG-IFN) alfa-2a 180 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Multicenter, Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS®) in Patients With Chronic Hepatitis D (CHD)
In Brief
A Phase 3 clinical trial evaluating Pegylated Interferon (PEG-IFN) alfa-2a for Hepatitis D, Chronic. Completed, enrolled 31 participants across 7 sites.
Detailed Summary
This study evaluated the efficacy and safety of 48-week treatment with pegylated interferon (PEG-IFN) alfa-2a (Pegasys) monotherapy in participants with chronic hepatitis D (CHD). Treatment was followed by 24 weeks of treatment-free follow-up.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis D, Chronic
CountriesRomania
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2005
Primary CompletionDec 2008
First PostedApr 2016
TodayJul 2026
First PostedApr 8, 2016
Enrollment StartOct 1, 2005
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 10.2 years ago
Interventions
Pegylated Interferon (PEG-IFN) alfa-2adrug
Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.